title: Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
abstract: OBJECTIVE
  To compare the efficacy and tolerability of daclatasvir and sofosbuvir (DCV + SOF) versus SOF and ribavirin (SOF + R) and versus peginterferon-alfa plus ribavirin (A/R) in patients infected with hepatitis C genotype 3.
  
  
  METHODS
  Clinical trials of SOF + R or A/R were identified in systematic literature reviews. The DCV+SOF population was adjusted via propensity score weighting to match average baseline characteristics to those reported for the comparator regimens.
  
  
  RESULTS
  The SVR12 rate was similar between DCV + SOF and SOF + R, and significantly higher with DCV + SOF than A/R. Rates of discontinuation due to AEs were similar or significantly lower in patients treated with DCV + SOF than SOF + R or A/R.
  
  
  CONCLUSIONS
  With its high efficacy and improved tolerability, DCV + SOF is an important treatment for hepatitis C genotype 3.
authors.affiliation: Analysis Group, Inc., 111 Huntington Avenue, 10th Floor, Boston, MA 02199, USA.
authors.forename: Elyse
authors.initials: E
authors.lastname: Swallow
authors.affiliation: Analysis Group, Inc., 111 Huntington Avenue, 10th Floor, Boston, MA 02199, USA.
authors.forename: Jinlin
authors.initials: J
authors.lastname: Song
authors.affiliation: Bristol-Myers Squibb, 100 Nassau Park Boulevard, Princeton, NJ 08540, USA.
authors.forename: Yong
authors.initials: Y
authors.lastname: Yuan
authors.affiliation: Bristol-Myers Squibb, 100 Nassau Park Boulevard, Princeton, NJ 08540, USA.
authors.forename: Anupama
authors.initials: A
authors.lastname: Kalsekar
authors.affiliation: Analysis Group, Inc., 111 Huntington Avenue, 10th Floor, Boston, MA 02199, USA.
authors.forename: Caroline
authors.initials: C
authors.lastname: Kelley
authors.affiliation: Analysis Group, Inc., 111 Huntington Avenue, 10th Floor, Boston, MA 02199, USA.
authors.forename: Fan
authors.initials: F
authors.lastname: Mu
authors.affiliation: Analysis Group, Inc., 111 Huntington Avenue, 10th Floor, Boston, MA 02199, USA.
authors.forename: Soomi
authors.initials: S
authors.lastname: Kim
authors.affiliation: Bristol-Myers Squibb, 100 Nassau Park Boulevard, Princeton, NJ 08540, USA.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Noviello
authors.affiliation: Analysis Group, Inc., 111 Huntington Avenue, 10th Floor, Boston, MA 02199, USA.
authors.forename: James
authors.initials: J
authors.lastname: Signorovitch
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002219:Carbamates; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines; D012254:Ribavirin / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000627:therapeutic use*; D059039:Standard of Care; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D016898:Interferon-alpha; D011759:Pyrrolidines; D012254:Ribavirin; D014633:Valine; C549273:daclatasvir; D000069474:Sofosbuvir
keywords: daclatasvir; hepatitis C genotype 3; matching-adjusted indirect comparison; peginterferon; ribavirin; sofosbuvir